Proposal for Aldafermin (NGM282, NGM Biopharmaceuticals)

Overview of Therapeutic Candidate:
Aldafermin (NGM282) is a synthetic analogue of fibroblast growth factor 19 (FGF19) that was engineered to recapitulate the beneficial metabolic actions of the native hormone while minimizing its inherent mitogenic and tumorigenic risks. Derived via recombinant DNA technology, Aldafermin incorporates targeted amino acid substitutions and deletions—specifically modifications within the N-terminal region—to separate its metabolic signaling from the pathways that lead to hepatocellular proliferation (Aaldijk et al., 2023, pp. 13–14). This engineered design permits Aldafermin to signal primarily through the fibroblast growth factor receptor 4 (FGFR4) in conjunction with the co-receptor β-Klotho (KLB), thereby maintaining efficacy in modulating bile acid synthesis and other metabolic processes while reducing the risk of cell proliferation (Henriksson & Andersen, 2020, pp. 8–9). Aldafermin belongs to the therapeutic class of FGF19 analogues, a group of drugs that have been explored for their capacity to regulate lipid metabolism, bile acid homeostasis, and energy balance. Historically, this class has been investigated for a range of metabolic liver diseases, including non-alcoholic steatohepatitis (NASH) and primary cholestatic disorders, due to its ability to target central pathways implicated in hepatic injury and fibrosis (Cate, 2022, pp. 13–16).

Therapeutic History:
The therapeutic history of Aldafermin is strongly rooted in its development for conditions characterized by metabolic liver dysfunction. Preclinical studies established that Aldafermin reduces hepatic steatosis, improves insulin sensitivity, and alleviates fibrosis in rodent models by suppressing deleterious bile acid toxicity and modulating hepatic metabolic gene expression (Fallowfield et al., 2021, pp. 9–10; Ocker, 2020, pp. 5–6). Clinically, Aldafermin has progressed through multiple phases of clinical trials, including a robust Phase 2 study (ClinicalTrials.gov, 2015) that enrolled patients with biopsy‐confirmed NASH to assess the effects on liver fat content, fibrosis markers, and other biochemical parameters. In these trials, Aldafermin was demonstrated to reduce absolute liver fat content as measured by MRI and to improve histologic features typical of NASH, such as inflammation and fibrotic changes (ClinicalTrials.gov, 2015; Cate, 2022, pp. 5–8). Moreover, its use has not been documented in veterinary medicine, and its development strategy has focused exclusively on targeting metabolic and cholestatic liver diseases in humans (Bhopale & Srinivasan, 2023, pp. 12–13; Cate, 2022, pp. 13–16). The cumulative clinical data indicate that in addition to its lipid-lowering and antifibrotic effects, Aldafermin has engaged its target pathway effectively as evidenced by reduced serum levels of 7α-hydroxy-4-cholesten-3-one (C4), a surrogate marker for CYP7A1 activity, further strengthening its candidacy for NASH treatment (Sanyal et al., 2021, pp. 2–3).

Mechanism of Action:
Aldafermin’s established mechanism of action is centered on its ability to mimic the endocrine activities of FGF19 while circumventing the undesirable mitogenic effects associated with native FGF19. Once administered, Aldafermin binds to the FGFR4–β-Klotho receptor complex on hepatocytes, a critical interaction that triggers downstream signaling pathways involved in hepatic metabolism. One of the principle biochemical actions of this receptor engagement is the suppression of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis. By inhibiting CYP7A1, Aldafermin effectively lowers bile acid production, reducing the accumulation of hydrophobic and potentially hepatotoxic bile acids that can exacerbate liver inflammation and fibrosis (Henriksson & Andersen, 2020, pp. 2–3; Ocker, 2020, pp. 5–6). In addition, this suppression of bile acid synthesis is associated with decreased serum levels of bile acid intermediates such as C4, providing a direct biochemical readout of Aldafermin’s target engagement.

Beyond bile acid modulation, Aldafermin also influences key metabolic pathways involved in lipid metabolism and mitochondrial β-oxidation. Preclinical evidence indicates that FGF19 analogues, including Aldafermin, induce the expression of peroxisome proliferator-activated receptor alpha (PPARα) target genes that regulate fatty acid oxidation (FAO), thereby promoting the catabolism of fatty acids within hepatocytes (Schumacher & Guo, 2019, pp. 27–31). This shift toward enhanced mitochondrial β-oxidation contributes to the reduction of intrahepatic lipid accumulation (steatosis) and alleviation of the lipotoxic environment that precipitates inflammatory cascades and fibrogenesis in NASH (Sanyal et al., 2021, pp. 2–3). Moreover, Aldafermin’s engagement of FGFR4 also indirectly modulates insulin sensitivity and energy homeostasis, accompanied by improvements in serum lipid profiles and body weight in certain preclinical models (Fallowfield et al., 2021, pp. 9–10; Henriksson & Andersen, 2020, pp. 8–9). The molecular interactions of Aldafermin, including its capacity to downregulate gene expression of CYP7A1 and to upregulate genes involved in mitochondrial β-oxidation, position it as a multifaceted modulator of hepatic metabolism (Sanyal et al., 2021, pp. 4–5; Schumacher & Guo, 2019, pp. 26–27).

Expected Effect:
Based on its well-characterized mechanism, the expected effect of Aldafermin in the treatment of NASH is multifactorial. Primarily, by binding to the FGFR4/β-Klotho receptor complex on hepatocytes, Aldafermin is anticipated to exert a potent inhibitory effect on CYP7A1, leading to decreased bile acid synthesis. This reduction in bile acid production is critical because excessive, hydrophobic bile acids contribute to hepatocyte injury, inflammation, and ultimately fibrosis through their detergent properties and pro-inflammatory signaling (Sanyal et al., 2021, pp. 2–3; Henriksson & Andersen, 2020, pp. 8–9). Simultaneously, Aldafermin’s stimulation of PPARα and related pathways is expected to upregulate mitochondrial β-oxidation genes, thereby enhancing the catabolism of free fatty acids and reducing hepatic lipid accumulation. This dual activity—suppressing lipogenesis while promoting fatty acid oxidation—is central to its hypothesized benefit in reducing hepatic steatosis and mitigating the metabolic stress that underlies NASH (Phan, 2024, pp. 14–16; Cate, 2022, pp. 5–8).

At the cellular level, hepatocytes express both FGFR4 and β-Klotho, ensuring that target engagement occurs in the relevant cell types affected by NASH pathology (Henriksson & Andersen, 2020, pp. 2–3). As Aldafermin engages these receptors, it is expected to initiate signaling cascades that result in decreased expression of genes involved in lipogenesis and concomitant increases in genes necessary for mitochondrial FAO. The net outcome should be a reduction in intracellular lipid droplet accumulation, improved mitochondrial function, and decreased secretion of inflammatory cytokines that contribute to the progressive fibrosis seen in NASH. Clinically, this molecular action has translated into measurable improvements; for instance, phase II trials have reported significant reductions in liver fat content as quantified by imaging modalities like MRI-PDFF, and improvements in fibrosis markers (ClinicalTrials.gov, 2015; Cate, 2022, pp. 5–8). Additionally, the biomarker profile observed in clinical studies—specifically, increased serum levels of FGF19 coupled with reductions in C4 levels—corroborates the mechanism by which Aldafermin modulates bile acid synthesis and metabolic function (Sanyal et al., 2021, pp. 2–3; Schumacher & Guo, 2019, pp. 27–31).

Overall Evaluation:
The overall evaluation of Aldafermin as a therapeutic candidate for NASH is largely favorable, with several notable strengths. First, its rational design as a non-mitogenic FGF19 analogue offers a significant safety advantage over native FGF19 by mitigating oncogenic risks while preserving metabolic efficacy (Aaldijk et al., 2023, pp. 13–14; Henriksson & Andersen, 2020, pp. 8–9). Second, the robust preclinical and clinical data supporting its mechanism of action—namely, the suppression of CYP7A1, reduction in toxic bile acid levels, and enhancement of mitochondrial β-oxidation—provide strong evidence of its potential to address key pathophysiologic drivers of NASH (Sanyal et al., 2021, pp. 2–3; Schumacher & Guo, 2019, pp. 27–31). Third, the observed clinical improvements in liver fat content, serum transaminases, and histological fibrosis scores during Phase II trials further validate its therapeutic promise (ClinicalTrials.gov, 2015; Cate, 2022, pp. 5–8).

Nonetheless, there are certain weaknesses and challenges that warrant consideration. Despite promising short-term efficacy signals, long-term safety and sustained efficacy data in broader NASH populations are still forthcoming, necessitating careful extended follow-up in Phase III trials. The modulation of bile acid synthesis by Aldafermin is associated with a rise in low-density lipoprotein (LDL) cholesterol, a recognized side effect that requires concomitant management with lipid-lowering agents such as rosuvastatin to mitigate potential cardiovascular risks (Ocker, 2020, pp. 5–6; Cate, 2022, pp. 5–8). Moreover, while the target engagement as indicated by reductions in serum C4 levels is promising, the clinical heterogeneity of NASH—with its complex interplay of metabolic, inflammatory, and fibrotic pathways—means that patient response might be variable, and a subset of patients may not achieve the desired clinical outcomes despite biochemical improvements. This variability underscores the need for the identification of robust predictive biomarkers (e.g., specific microbiome profiles or genetic variants) to optimize patient selection (Fallowfield et al., 2021, pp. 9–10; Cate, 2022, pp. 13–16). Furthermore, there remains some uncertainty regarding the complete spectrum of downstream molecular effects following FGFR4 activation, and whether alternate signaling pathways may contribute to off-target effects in certain patient subsets (Henriksson & Andersen, 2020, pp. 9–10; Schumacher & Guo, 2019, pp. 26–27).

Taken together, Aldafermin exhibits several compelling attributes as a candidate for repurposing in NASH. Its targeted mechanism of action presents a rational strategy for simultaneously addressing hepatic steatosis, inflammation, and fibrosis by coupling the inhibition of bile acid synthesis with enhanced mitochondrial β-oxidation. The clinical data, including reductions in hepatic fat and improvements in fibrosis biomarkers, support its potential utility in this challenging disease. However, the weaknesses—primarily relating to lipid profile changes, patient response variability, and the need for long-term safety data—should be carefully weighed as part of an overall risk-benefit assessment. Continued rigorous clinical investigation, including larger and longer-duration studies, will be essential to fully validate Aldafermin’s efficacy and safety profile in NASH before its widespread adoption in clinical practice (Aaldijk et al., 2023, pp. 14–15; Henriksson & Andersen, 2020, pp. 9–10; Cate, 2022, pp. 5–8).

In conclusion, based on the comprehensive review of the biomedical, clinical, and biochemical literature available, Aldafermin emerges as a highly promising therapeutic candidate for NASH. Its well-defined molecular rationale, robust target engagement data, and encouraging clinical outcomes support further development and clinical evaluation. While certain challenges remain—most notably, the management of its lipid-related side effects and the need for long-term outcome data—the overall profile of Aldafermin justifies continued investment and research into its application as a metabolic modulator and antifibrotic agent in the treatment of non-alcoholic steatohepatitis (Aaldijk et al., 2023, pp. 14–15; Henriksson & Andersen, 2020, pp. 9–10; Cate, 2022, pp. 5–8).

References:

Aaldijk, A. S., Verzijl, C. R. C., Jonker, J. W., & Struik, D. (2023). Biological and pharmacological functions of the FGF19- and FGF21-coreceptor β-Klotho. Frontiers in Endocrinology, 14, 1150222. https://doi.org/10.3389/fendo.2023.1150222

Bhopale, K. K., & Srinivasan, M. P. (2023). Therapeutics for metabolic dysfunction-associated fatty liver disease (MAFLD). Livers, 3, 597–617. https://doi.org/10.3390/livers3040040

Cate, W. (2022). Clinical trials for NASH treatment: Dual agonist drugs as potential treatment methods. Unknown Journal

ClinicalTrials.gov. (n.d.). Search results for Aldafermin OR NGM282 AND Non-alcoholic steatohepatitis OR NASH. https://clinicaltrials.gov/

Fallowfield, J. A., Jimenez-Ramos, M., & Robertson, A. (2021). Emerging synthetic drugs for the treatment of liver cirrhosis. Expert Opinion on Emerging Drugs, 26(2), 149–163. https://doi.org/10.1080/14728214.2021.1918099

Henriksson, E., & Andersen, B. (2020). FGF19 and FGF21 for the treatment of NASH—Two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human. Frontiers in Endocrinology, 11, 601349. https://doi.org/10.3389/fendo.2020.601349

Ocker, M. (2020). Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma. World Journal of Gastroenterology, 26(3), 279–290. https://doi.org/10.3748/wjg.v26.i3.279

Phan, P. (2024). Exploring endocrine FGFs—Structures, functions and biomedical applications. Unknown Journal

Sanyal, A. J., Ling, L., Beuers, U., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Hirschfield, G. M. (2021). Potent suppression of hydrophobic bile acids by Aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. JHEP Reports, 3, 100255. https://doi.org/10.1016/j.jhepr.2021.100255

Schumacher, J. D., & Guo, G. L. (2019). Pharmacologic modulation of bile acid–FXR–FGF15/FGF19 pathway for the treatment of nonalcoholic steatohepatitis. Handbook of Experimental Pharmacology, 325–357. https://doi.org/10.1007/164_2019_228

Study of NGM282 in patients with nonalcoholic steatohepatitis (NASH) (ClinicalTrials.gov Identifier: NCT02443116). (2015). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02443116
